The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...

Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Johnson & Johnson announced positive topline results from the Phase 2b JASMINE study of adults living with systemic lupus erythematosus and the ...

A recent VDOT study coupled with new community input is helping shape the future of safety and traffic flow on Virginia ...

Almirall SA ($GB:0O9B) announced an update on their ongoing clinical study. Study Overview: Almirall S.A. is running a phase 2 trial called “A ...

Australian Mines is gearing up to restart drilling at its Flemington scandium-nickel-cobalt project in NSW next month.

"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

The company confirmed the publication of its successful clinical case series in Frontiers in Immunology, a peer-reviewed scientific journal, and received confirmation from the U.S. Food and Drug ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R fully ...